Tazemetostat not checked

Epizyme, Inc. · EPZ-6438 · E7438

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
17 in total · 5 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Stage 1 (Phase 1b): Tazemetostat was escalated from a starting dose of 400 mg orally twice daily to 600 mg orally twice daily to 800 mg PO twice daily in 28-day cycles as tolerated in a standard 3 + 3 design. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy. Following implementation of the urgent…”In the company’s words, NCT04224493 on ClinicalTrials.gov
Tested for
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Main trialPhase 3
“The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial studied the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2…”In the company’s words, NCT04224493 on ClinicalTrials.gov
Other names
EPZ-6438 · E7438 · IPN60200 · Tazverik

Other drugs for Relapsed/Refractory Follicular Lymphoma

All 76 drugs for Relapsed/Refractory Follicular Lymphoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials17

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 13 Feb 2027 A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Phase 2Completed Jun 2018 Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Phase 2Terminated 22 Mar 2022 SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Phase 2Completed 26 Feb 2024 A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Phase 2Withdrawn 6 Apr 2029 A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
Phase 1/2Completed 24 Aug 2021 Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Phase 1/2Withdrawn 5 Jul 2023 A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
Phase 1/2Terminated 4 Nov 2024 A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
Phase 1/2Terminated 26 Sep 2025 A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
Phase 1Completed 8 Jan 2019 Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
Phase 1Completed 31 Oct 2019 Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Phase 1Completed 19 Jun 2021 EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Phase 1Completed 3 Apr 2023 Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Phase 1Terminated 14 Jun 2024 Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Phase 1Terminated 12 Mar 2025 A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Phase 2Ended not given CAIRE : COMBINING EPIGENETIC AND IMMUNE THERAPY TO BEAT CANCER
Phase 1/2Authorised not given Epi-RCHOP A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL) patients treated by R-CHOP
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tazemetostat

Following is part of Solo: you see every change to Tazemetostat the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in